|
Name |
cyclo(L-Phe-trans-4-hydroxy-L-Pro)
|
Molecular Formula | C14H16N2O3 | |
IUPAC Name* |
(3S,7R,8aS)-3-benzyl-7-hydroxy-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
C1[C@H](CN2[C@@H]1C(=O)N[C@H](C2=O)CC3=CC=CC=C3)O
|
|
InChI |
InChI=1S/C14H16N2O3/c17-10-7-12-13(18)15-11(14(19)16(12)8-10)6-9-4-2-1-3-5-9/h1-5,10-12,17H,6-8H2,(H,15,18)/t10-,11+,12+/m1/s1
|
|
InChIKey |
PYQJYHACQOBZLF-WOPDTQHZSA-N
|
|
Synonyms |
cyclo(L-Phe-trans-4-hydroxy-L-Pro); 118477-06-8; Cyclo(L-phenylalanyl-trans-4-hydroxy-L-proline); (3S,7R,8aS)-3-benzyl-7-hydroxy-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; L-Phe-trans-4-hydroxy-L-Pro; CHEMBL3740025; SCHEMBL13657922; BDBM163707; ZINC82047600; AKOS032948256; (4R)-4-Hydroxycyclo(L-Pro-L-Phe-); Cyclo L-OH-Pro-L-Phe (Fr. 1-4); Cyclo-(L-phenylalanyl-4R-hydroxy-L-proline)
|
|
CAS | NA | |
PubChem CID | 10467786 | |
ChEMBL ID | CHEMBL3740025 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 260.29 | ALogp: | 0.4 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.6 | Aromatic Rings: | 3 |
Heavy Atoms: | 19 | QED Weighted: | 0.793 |
Caco-2 Permeability: | -5.209 | MDCK Permeability: | 0.00001710 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.195 |
Human Intestinal Absorption (HIA): | 0.09 | 20% Bioavailability (F20%): | 0.747 |
30% Bioavailability (F30%): | 0.937 |
Blood-Brain-Barrier Penetration (BBB): | 0.242 | Plasma Protein Binding (PPB): | 21.57% |
Volume Distribution (VD): | 0.614 | Fu: | 68.09% |
CYP1A2-inhibitor: | 0.026 | CYP1A2-substrate: | 0.073 |
CYP2C19-inhibitor: | 0.088 | CYP2C19-substrate: | 0.556 |
CYP2C9-inhibitor: | 0.062 | CYP2C9-substrate: | 0.521 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.267 |
CYP3A4-inhibitor: | 0.076 | CYP3A4-substrate: | 0.381 |
Clearance (CL): | 4.012 | Half-life (T1/2): | 0.619 |
hERG Blockers: | 0.037 | Human Hepatotoxicity (H-HT): | 0.935 |
Drug-inuced Liver Injury (DILI): | 0.695 | AMES Toxicity: | 0.025 |
Rat Oral Acute Toxicity: | 0.298 | Maximum Recommended Daily Dose: | 0.934 |
Skin Sensitization: | 0.162 | Carcinogencity: | 0.177 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
Respiratory Toxicity: | 0.119 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005847 | 1.000 | D05EPM | 0.371 | ||||
ENC005969 | 0.706 | D06BYV | 0.348 | ||||
ENC005971 | 0.683 | D05OIS | 0.328 | ||||
ENC005484 | 0.683 | D03RZV | 0.324 | ||||
ENC005481 | 0.532 | D0Z9NZ | 0.320 | ||||
ENC005972 | 0.516 | D0R1BD | 0.315 | ||||
ENC005846 | 0.516 | D07RGW | 0.307 | ||||
ENC001910 | 0.516 | D0U5RT | 0.303 | ||||
ENC003591 | 0.500 | D08EOD | 0.301 | ||||
ENC005997 | 0.494 | D07HOF | 0.300 |